Walleye Capital
XGN icon

Walleye Capital’s Exagen XGN Stock Holding History

Walleye Capital’s Portfolio XGN Stock Details XGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-20,838
Closed -$127K – 5070
2025
Q4 		$127K Sell
20,838
-51,876
-71% -$472K ﹤0.01% 3770
2025
Q3 		$799K Buy
+72,714
New +$644K ﹤0.01% 2268
2021
Q3 		– Sell
-12,398
Closed -$186 – 1837
2021
Q2 		$186 Buy
+12,398
New +$190K 0.01% 1074

Other funds holding XGN

Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $690M AUM 57.92% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $107M AUM
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
FCM
FourWorld Capital Management New York $196M AUM 42.39% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
MBAM
Mink Brook Asset Management West Palm Beach, Florida $179M AUM 37.68% 1-Year Est. Return

Walleye Capital's XGN Position: Q1 2026 in Review

Walleye Capital sold out of Exagen (XGN) in Q1 2026, closing a stake of 20,838 shares — an estimated $127K sold.

Walleye Capital first reported a position in XGN in Q2 2021 and held it in 3 quarters. The position peaked at $799K in Q3 2025. 61 funds tracked by Wall St. Rank hold XGN as of Q1 2026.

  • Walleye Capital reported no remaining Exagen position as of Q1 2026 after selling out during the quarter.
  • Walleye Capital sold 20,838 Exagen shares in Q1 2026, an estimated $127K.
  • Walleye Capital first reported a position in Exagen in Q2 2021 and held it in 3 quarters.
  • Walleye Capital's Exagen position peaked at $799K in Q3 2025.
  • 61 funds tracked by Wall St. Rank held Exagen as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.